The antibody was purified by affinity chromatography, and conjugated with PE/Cy7 under optimal conditions. The solution is free of unconjugated PE/Cy7 and unconjugated antibody.
Concentration:
0.2 mg/ml
Storage & Handling:
The antibody solution should be stored undiluted at 4°C and protected from prolonged exposure to light. Do not freeze.
Application:
FC
Recommended Usage:
Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.
Application Notes:
Additional reported applications (for the relevant formats) include: immunohistochemistry1,2 of acetone-fixed frozen sections, and induction of B cell proliferation1.
Application References:
1. Oliver, A.M., et al., 1997. J. Immunol. 158:1108. 2. Howard, M., et al., 1993. Science 262:1056.
C57BL/6 mouse splenocytes stained with 90 PE/Cy7
Description:
CD38 is a 42 kD glycoprotein, also known as T10. It is an ADP-ribosyl hydrolase, expressed on B cells, NK cells, subset of T cells, brain, muscle, and kidney. In the mouse, CD38 expression is downregulated on mouse germinal center B cells and plasma cells, whereas this is not the case for humans. By functioning as both a cyclase and a hydrolase, CD38 mediates lymphocyte activation, as well as adhesion and the metabolism of cADPR and NAADP. CD31 is the ligand of CD38.
Other Names:
T10
Structure:
ADP-ribosyl hydrolase, 42 kD
Distribution:
B cells, NK cells, T cell subset, brain, muscle, kidney
Function:
Regulation of cellular activation/proliferation, adhesion, metabolism of cADPR and NAADP
Ligand Receptor:
CD31, hyaluronic acid
Antigen References:
1. Barclay, A.N. et al., 1997. The Leukocyte Antigen FactsBook, Academic Press. 2. Shubinsky, G., et al., 1997. Immunity 7:315. 3. Cesano, A., et al., 1998. J. Immunol. 160:1106. 4. Cockayne, D.A., et al., 1998. Blood 92:1324.
